Spruce Biosciences, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
Spruce Biosciences, Inc. (SPRB) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $300.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-09.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-03-09
- Spruce Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2022-12-31 was $2.00M, a 566.33% increase year-over-year.
- Spruce Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2022-09-30 was $0.00, a 100.00% decline year-over-year.
- Spruce Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2022-06-30 was $0.00, a 100.00% decline year-over-year.
- Spruce Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2022-03-31 was $1.00K, a 99.89% decline year-over-year.
- Spruce Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $300.00K, a 0.00% change from fiscal 2024.
- Spruce Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $300.00K.
- Spruce Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $2.00M, a 0.00% change from fiscal 2021.
- Spruce Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2021 was $2.00M, a 566.67% increase from fiscal 2020.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|---|---|---|
| 2025-12-31 | $300.00K 10-K · filed 2026-03-09 | |||
| 2024-12-31 | $300.00K 10-K · filed 2026-03-09 | |||
| 2022-12-31 | $2.00M derived: 10-K 12 month − 3 quarters · filed 2023-03-16 | $2.00M derived: sum of 2 quarters · filed 2023-03-16 | $2.00M derived: sum of 3 quarters · filed 2023-03-16 | $2.00M 10-K · filed 2023-03-16 |
| 2022-09-30 | $0.00 10-Q · filed 2022-11-10 | $0.00 derived: sum of 2 quarters · filed 2022-11-10 | $1.00K derived: sum of 3 quarters · filed 2022-11-10 | $301.00K derived: sum of 4 quarters · filed 2023-03-16 |
| 2022-06-30 | $0.00 10-Q · filed 2022-08-10 | $1.00K 10-Q · filed 2022-08-10 | $301.00K derived: sum of 3 quarters · filed 2023-03-16 | $401.00K derived: sum of 4 quarters · filed 2023-03-16 |
| 2022-03-31 | $1.00K 10-Q · filed 2022-05-11 | $301.00K derived: sum of 2 quarters · filed 2023-03-16 | $401.00K derived: sum of 3 quarters · filed 2023-03-16 | $1.20M derived: sum of 4 quarters · filed 2023-03-16 |
| 2021-12-31 | $300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $400.00K derived: sum of 2 quarters · filed 2023-03-16 | $1.20M derived: sum of 3 quarters · filed 2023-03-16 | $2.00M 10-K · filed 2023-03-16 |
| 2021-09-30 | $100.00K 10-Q · filed 2021-11-15 | $900.00K derived: sum of 2 quarters · filed 2021-11-15 | $1.70M 10-Q · filed 2021-11-15 | $1.80M derived: sum of 4 quarters · filed 2022-03-14 |
| 2021-06-30 | $800.00K 10-Q · filed 2021-08-10 | $1.60M 10-Q · filed 2021-08-10 | $1.70M derived: sum of 3 quarters · filed 2022-03-14 | $2.00M derived: sum of 4 quarters · filed 2022-03-14 |
| 2021-03-31 | $900.00K 10-Q · filed 2021-05-12 | $900.00K derived: sum of 2 quarters · filed 2022-03-14 | $1.20M derived: sum of 3 quarters · filed 2022-03-14 | |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | $300.00K derived: sum of 2 quarters · filed 2022-03-14 | $300.00K 10-K · filed 2022-03-14 | |
| 2020-09-30 | $300.00K 10-Q · filed 2020-11-18 | $300.00K 10-Q · filed 2020-11-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |